Related Experiment Video
Updated: Jun 10, 2026

Homogeneous Glycoconjugate Produced by Combined Unnatural Amino Acid Incorporation and Click-Chemistry for Vaccine Purposes
Published on: December 19, 2020
Global use of Haemophilus influenzae type b conjugate vaccine
Linda R Ojo1, Rosalyn E O'Loughlin, Adam L Cohen
1Respiratory Diseases Branch, Division of Bacterial Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road NE, MS C-23, Atlanta, GA 30333, USA.
Abstract:
Haemophilus influenzae type b (Hib) conjugate vaccines have been underutilized globally. We report progress in global use of Hib vaccines included in national immunization schedules. The number of countries using Hib vaccine increased from 89/193 (46%) in 2004 to 158/193 (82%) by the end of 2009. The increase was greatest among low-income countries eligible for financial support from the GAVI Alliance [13/75 (17%) in 2004, 60/72 (83%) by the end of 2009], and can be attributed to various factors. Additional efforts are still needed to increase vaccine adoption in lower middle income countries [20/31 (65%) by the end of 2009].
Related Concept Videos
Vaccinations
Streptococcal Pharyngitis
Bacterial Meningitis
Poliomyelitis
Conjugation
Bacterial Meningitis I: Introduction

